Physician profile
Jason Keith Ely
NPI 1104595396
$878.48
in general payments reported to CMS, 2019-2025
17 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.11 · 2022: $50.33 · 2023: $277 · 2024: $280 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $205.03 | 2022-2025 | |
| Novo Nordisk INC | $115.48 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $86.64 | 2023-2025 | Mounjaro, Zepbound |
| Renalytix Ai, INC. | $70.22 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astrazeneca Pharmaceuticals LP | $66.31 | 2024-2025 | Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $61.45 | 2023 | Livalo, Seglentis |
| Xeris Pharmaceuticals, INC. | $56.06 | 2021-2022 | |
| Ardelyx, INC. | $37.97 | 2023 | Ibsrela |
| Indivior INC. | $37.80 | 2023-2024 | Sublocade |
| Davol INC. | $22.32 | 2022 | |
| Lundbeck LLC | $22.20 | 2025 | Rexulti |
| Almatica Pharma LLC | $19.80 | 2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $19.60 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $15.24 | 2023 | Nexlizet, Contrave, Nexletol |
| Exact Sciences Corporation | $15.13 | 2024 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.63 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.